Singapore markets closed
Straits Times Index
3,296.12 +12.18 (+0.37%) S&P 500
4,532.76 -44.35 (-0.97%) Dow
35,028.65 -339.82 (-0.96%) Nasdaq
14,340.25 -166.64 (-1.15%) BTC-USD
41,961.16 +590.82 (+1.43%) CMC Crypto 200
996.43 +1.68 (+0.17%)
MannKind Corporation (MNKD)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 3.9700 |
| Open | 3.9700 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 1000 |
| Day's range | 3.9700 - 4.1900 |
| 52-week range | 3.1200 - 6.2500 |
| Volume | |
| Avg. volume | 2,323,449 |
| Market cap | 1.01B |
| Beta (5Y monthly) | 1.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3230 |
| Earnings date | 23 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.25 |
- Zacks
MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and 8.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Will MannKind (MNKD) Report Negative Q3 Earnings? What You Should Know
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
© 2022 Yahoo. All rights reserved.
